Meeting
2023 ASCO Annual Meeting
Intralesional therapy, limb infusion/perfusion, and immune checkpoint inhibitors as first-line therapy in surgically unresectable melanoma in-transit metastases.
Authors
Danielle K DePalo
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Danielle K DePalo , Syeda Mahrukh Hussnain Naqvi , David W. Ollila , Tina J. Hieken , Matthew Stephen Block , Winan J. van Houdt , Michel W.J.M. Wouters , Nethanel Asher , Kristy Kummerow Broman , Zoey Duncan , Matilda Anderson , David E. Gyorki , John T. Vetto , Jane Yuet Ching Hui , Robyn P.M. Saw , Serigne N. Lo , Youngchul Kim , Alexander Christopher Jonathan Van Akkooi , Roger Olofsson Bagge , Jonathan S. Zager
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9574)
DOI
10.1200/JCO.2023.41.16_suppl.9574
Abstract #
9574
Poster Bd #
337
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Neo-adjuvant T-VEC plus nivolumab combination therapy for resectable early-stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: The NIVEC trial.
First Author: Maartje W. Rohaan
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma.
First Author: Young-Gyu Park
Poster
2022 ASCO Quality Care Symposium
Duration of first-line immune checkpoint inhibitor treatment in U.S. patients with melanoma, non–small cell lung cancer, and renal cell carcinoma.
First Author: Alia Rawji
Poster
2021 ASCO Annual Meeting
The use of cryoablation to overcome resistance to PD-1 blockade in unresectable melanoma.
First Author: Meghan Mooradian